Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma

Matias A. Avila¹*, Carmen Berasain¹*, Luis Torres², Antonio Martin-Duce³, Fernando J. Corrales¹, Heping Yang⁴, Jesús Prieto¹, Shelly C. Lu⁴, Juan Caballera³, Juan Rodés³ and José M. Mato¹

¹División de Hepatología y Terapia Génica, Departamento de Medicina Interna, Universidad de Navarra, 2Departamento de Bioquímica y Biología Molecular, Universitat de València, Burjassot and 3Servicio de Cirugía, Hospital Príncipe de Asturias, Alcalá de Henares, Spain; *Center for Disease Liver Research and Division of Gastrointestinal Liver Diseases, Department of Medicine, University of Southern California School of Medicine, Los Angeles, CA, USA; and 2Servicio de Hepatología, Institut de Malalties Digestives, Hospital Clinic, IDIBAPS, Universidad de Barcelona, Barcelona, Spain

Background/Aims: It has been known for at least 50 years that alterations in methionine metabolism occur in human liver cirrhosis. However, the molecular basis of this alteration is not completely understood. In order to gain more insight into the mechanisms behind this condition, mRNA levels of methionine adenosyltransferase (MATIA), glycine methyltransferase (GNMT), methionine synthase (MS), betaine homocysteine methyltransferase (BHMT) and cystathionine-β-synthase (CBS) were examined in 26 cirrhotic livers, five hepatocellular carcinoma (HCC) tissues and ten control livers.

Methods: The expression of the above-mentioned genes was determined by quantitative RT-PCR analysis. Methylation of MATIA promoter was assessed by methylation-sensitive restriction enzyme digestion of genomic DNA.

Results: When compared to normal livers MATIA, GNMT, BHMT, CBS and MS mRNA contents were significantly reduced in liver cirrhosis. Interestingly, MATIA promoter was hypermethylated in the cirrhotic liver. HCC tissues also showed decreased mRNA levels of these enzymes.

Conclusions: These findings establish that the abundance of the mRNA of the main genes involved in methionine metabolism is markedly reduced in human cirrhosis and HCC. Hypermethylation of MATIA promoter could participate in its reduced expression in cirrhosis. These observations help to explain the hypermethioninemia, hyperhomocysteinemia and reduced hepatic glutathione content observed in cirrhosis.

Key words: Cirrhosis; DNA methylation; Hepatocarcinoma; Liver; Methionine.

The liver has the dual task of converting methionine, via S-adenosylmethionine (AdoMet) and S-adenosylhomocysteine (AdoHcy), into homocysteine, followed by reconversion of homocysteine into methionine while feeding the transsulfuration pathway that leads to the formation from homocysteine of cysteine and glutathione (GSH) (Fig. 1). The two pathways are co-ordinated by AdoMet which inhibits the synthesis of methionine from homocysteine and activates cystathionine-β-synthase (CBS), the first step of the transsulfuration pathway (1,2). Moreover, AdoMet activates glycine N-methyltransferase (GNMT), an enzyme which accounts for about 1% of the hepatic cytosol (3), and whose main function is to remove excess AdoMet (1,2). The expression of GNMT, betaine homocysteine methyltransferase (BHMT) and CBS is confined mainly to the liver, whereas the expression of methionine synthase (MS) occurs in all tissues (1,2). There are two genes coding for methionine adenosyltransferase (MAT), the enzyme that converts methionine into AdoMet, one (MATIA) expressed exclusively in the liver and a second gene (MAT2A) expressed in all tissues and fetal liver (4). As a consequence of this liver-speci-
fic expression of genes involved in methionine metabolism, and although all tissues can synthesize and utilize AdoMet, the liver is the main place for the metabolism of this amino acid. In humans, up to 85% of all methylation reactions and as much as 48% of methionine metabolism occur in the liver (5).

Human liver cirrhosis has been known to be associated with alterations of methionine metabolism for at least 50 years (6). Many patients with alcoholic liver cirrhosis have increased serum methionine (6–8) and homocysteine (9), abnormal clearance of methionine after an oral load of this amino acid (7,8), and diminished hepatic GSH content (10) and MAT activity (11,12). Methionine metabolism has also been investigated in various experimental models of liver disease. Ethanol and CCL4-induced liver injury are associated with a reduction in hepatic AdoMet and an increase in AdoHcy, overall hepatic DNA hypomethylation, reduced hepatic GSH content, and increased serum homocysteine (13–18). The importance of this alteration in the metabolism of methionine for the progression of the disease has been substantiated by the numerous publications showing in experimental models that AdoMet administration reduces liver damage induced by a variety of agents (15–23), and by the recent finding demonstrating that AdoMet treatment improves survival in patients with alcoholic liver cirrhosis (24). However, knowledge of the molecular basis of this alteration of methionine metabolism in human liver cirrhosis and of the mechanism of action of AdoMet is limited. Thus we have examined the mRNA level of MATlA, GNMT, MS, BHMT and CBS in 26 cirrhotic livers, five hepatocellular carcinoma (HCC) tissues and ten control liver tissues.

Materials and Methods

Patients

We have studied a group of 26 patients (17 males and 9 females, mean age 54±8.5 years) with liver cirrhosis of different etiology (13 HCV cirrhosis, 10 alcoholic cirrhosis, one HBY cirrhosis, one cryptogenic cirrhosis and one primary biliary cirrhosis, PBC). The control group for the cirrhotic patients consisted of 10 subjects in whom a cholecystectomy was performed for the treatment of a symptomatic cholelithiasis and who consented to be submitted to a liver biopsy during the surgical procedure. Liver samples were immediately frozen and kept at –80°C until processed. In the subjects from the control group, both the liver function tests and the liver biopsy were normal. This study was approved by the human research review committee of the University of Navarra. Hospital Clinic and Hospital Príncipe de Asturias. Cancerous liver tissues were obtained from five liver patients undergoing surgical resection for primary HCC (25). The contamination of HCC samples with noncancerous tissue was less than 5% as determined by histopathology. The control group for the HCC patients consisted of normal liver tissue obtained from normal liver included in the resected liver specimens of six patients with metastatic colon or breast carcinoma. We were blinded to the clinical characteristics (whether there was hepatitis B or C, etc.). This was mandated by the Institutional Review Board of the University of Southern California School of Medicine, from where these liver specimens were obtained. These tissues were immediately frozen in liquid nitrogen for subsequent isolation of RNA. Written informed consent was obtained from each patient. The study was approved by University of Southern California School of Medicine’s human research review committee.

RT-PCR studies

Total RNA was extracted from liver biopsies as previously described (25). Aliquots of 2 μg were reverse transcribed using M-MLV Reverse Transcriptase (Gibco Life Technologies, MD, USA) and subsequently amplified by polymerase chain reaction (PCR) using the BioTag DNA Polymerase (Bioline, UK). The primers used for the different genes studied were: 5’-ATG TCA CCC GCG CTC CAA GAC-3’ and 5’-TCC AGA AGT CTT TTG GCC TGC-3’ for MS, 5’-GTC ATG CAG ACC TTC ACC TTC TA-3’ and 5’-CTC CTT CAT GAT CCT CAC TG-3’ for BHMT, 5’-ACA TGA CCA AGT TCC TGA GGC CAG-3’ and 5’-GCC AGC AAG TTC AGC AAG TC-3’ for CBS, 5’-AGG GCC TCT TCA GTG TGA CG-3’ and 5’-AGG GCT GAT GAA GTC GCC CAG CA-3’ for GNMT, 5’-TCT CCT CCA GCA TGG TGA TG-3’ and 5’-GTT CAC ATC GGA GTC TG for MATlA and 5’-ATG AAG GTG GTA ACC-3’ and 5’-TAT CAG CAG CTT GCC-3’ for NBS. To avoid amplification of genomic DNA which could contaminate our RNA preparations, these primers were designed flanking intronic sequences. 18S RNA was simultaneously amplified using the Alternate 18S Internal Standards primers set (Ambion, TX, USA) and served as an internal loading control. Reactions were resolved in a 2% agarose gel, stained with ethidium bromide and quantitated using the Molecular Analyst software (Bio-Rad, Hercules, CA, USA). The 100-bp DNA Ladder molecular weight standards from Gibco Life Technologies were used.

DNA extraction and Southern blot analysis

Genomic DNA was prepared from control and cirrhotic liver samples as described previously (26). Aliquots of high molecular weight DNA

![DNA Extraction and Southern blot Analysis](image-url)
Methionine metabolism in cirrhotic human liver

(10 μg) were digested to completion with DraI and then either MspI or HpaII restriction enzymes (Boehringer Mannheim, Mannheim, Germany). After digestion, samples were loaded on agarose gels, electrophoresed and blotted onto NYTRAN membranes (Schleicher & Schuell, Keene NH, USA). Hybridizations were carried out with a 0.89 kb probe derived from the human MATIA promoter (DraI-DraI fragment encompassing from nucleotide −589 to −1479) (27) labeled with [α-32P]dCTP (3000 Ci/mmol, Amersham, Little Chalfont, UK) by random priming using the Megaprime DNA labeling system (Amersham) as reported (26). Membranes were then exposed to X-ray films.

RNA extraction and Northern blot analysis
Total RNA was extracted from control livers and HCC samples by the guanidinium thiocyanate method as previously described (25). Aliquots (20 μg) of total RNA were electrophoresed, blotted, prehybridized and hybridized as described (25). The probes (25) were labeled with [c+32P] dCTP (3000 Ci/mmol, Amersham, Little Chalfont, UK) by random priming using the Megaprime DNA labeling system (Amersham). Equal loading of the gels was assessed by hybridization with an 18s ribosomal RNA probe. Quantitation was performed by scanning densitometry of the x-ray films.

Serum methionine and total homocysteine (tHcy) determination
Serum methionine was determined as described (17). Total serum homocysteine (tHcy) was measured as reported (28), with the modifications described in Deulofeu et al. (29).

Statistics
All data are means±SEM. The Mann-Whitney unpaired test was used to compare groups.

Results
Reduced mRNA levels of the main enzymes involved in methionine metabolism in cirrhotic livers
We assessed MATIA mRNA levels by RT-PCR in 26 cirrhotic and ten normal livers (Fig. 2). Only three cirrhotic livers (11%) showed MATIA mRNA abundance comparable to that measured in normal livers. Decreased MATIA mRNA content in liver was observed in 15 cirrhotic livers (58%). In eight cirrhotic patients (31%) hepatic MATIA mRNA level was very low or non-detectable. MAT2A expression was not induced in any of the cirrhotic patients (not shown). We also assessed GNMT, MS, BHMT and CBS mRNA content in the same cirrhotic and normal livers by RT-PCR (Fig. 2). GNMT, MS, BHMT and CBS mRNA was very low or undetectable in the majority of the cirrhotic samples (54%, 65%, 69% and 58%, respectively).

The percent of cirrhotic livers showing reduced mRNA abundance for GNMT, MS, BHMT and CBS was 42%, 35%, 19% and 15%, respectively. In the case of GNMT, BHMT and CBS, one, three and seven patients, respectively, showed mRNA levels similar to those determined in normal livers. None of the cirrhotic livers

Fig. 2. Expression of methionine metabolism genes in the liver of cirrhotic and control patients. C: normal livers (controls). Cirrhotics were divided into three groups according to the levels of expression of the different genes tested: group 1: patients with very low or non-detectable expression, group 2: patients with a level of expression lower than controls, group 3: patients with a level of expression similar to controls. The number of patients per group is indicated for each gene analyzed. Serum albumin (HSA) expression in control and cirrhotic patients is also shown. Representative RT-PCR reactions are shown for the 26 patients and 10 normal livers. 18s ribosomal RNA was used as internal control. The left lane of each gel shows the molecular weight markers, the most intense band corresponds to 600 bp.
showed MS mRNA levels comparable to those measured in normal livers. Human serum albumin (HSA) mRNA level was normal in 50% of the cirrhotic livers, reduced in 31% of the tissues, and very low or nondetectable in 19% of the samples (Fig. 2). Patients with a marked reduction in the expression of a given gene (group one) tended to be in this same group for all genes tested. For instance, out of the 14 patients in group one for GNMT (Fig. 2), the same 14 patients were in group one for BHMT, 12 in group 1 for CBS and 11 in group 1 for MS. The percent of livers with very low or non-detectable levels of mRNA for the various genes of methionine metabolism analyzed was higher for tissues from patients with HCV cirrhosis than with alcoholic cirrhosis (Fig. 3).

In order to evaluate if the reduced expression of the various genes involved in methionine metabolism was related to the severity of the disease, expressed as the Child-Pugh score (30), patients were divided into two groups. One group (group 1) included patients showing normal or only reduced levels of mRNA for at least three of the five genes analyzed involved in methionine metabolism. The second group (group 2) included those patients with very low or undetectable levels of mRNA for all or four of the five genes analyzed involved in methionine metabolism. The mean value for the Child-Pugh score was significantly higher in the cirrhotic patients in group 2 (9.0±0.7) than in the cirrhotic patients in group 1 (7.1±0.4, p<0.03).

The mean value for tHcy was significantly higher in the cirrhotic patients in group 2 (17.0±2.0 μM) than in group 1 (12.0±1.6 μM, p<0.05). In agreement with previous results (9), the tHcy concentration in our group of cirrhotics (14.1±1.3 μM) was significantly higher than in the control group (8.1±0.9 μM, p<0.01). In agreement with previous publications (6–8), fasting serum methionine in cirrhotics (106.3±34.7 μM) was higher than in the control group (30.8±4.8 μM, p<0.01). Differences in methionine concentration in cirrhotic patients in groups 1 (46.2±8.6 μM) and 2 (171.8±68.1 μM, p<0.01) were also statistically significant.

Reduced mRNA levels of the main enzymes involved in methionine metabolism in HCC tissues
We have reported a switch in gene expression from MAT1A to MAT2A in various human-derived cancer cell lines and HCC tissues resected from patients (25).

Fig. 3. Expression of liver methionine metabolizing genes and serum albumin (HSA) in cirrhotic patients according to the etiology of the disease: HCV cirrhosis or alcoholic cirrhosis. Patient groups are as defined in the legend to Fig. 2. The percentage of patients in each group is shown.
As expected, in the five HCC tissues used in the present experiments the mRNA content of \textit{MAT2A} increased about 6-fold in respect to the average control liver (Fig. 4A) and in HCC tissues \textit{MAT2A} mRNA content was very low or non-detectable (not shown). We next examined the mRNA abundance by RT-PCR of the main enzymes of methionine metabolism in these HCC tissues. \textit{BHMT}, \textit{CBS}, \textit{GNMT} and \textit{MS} mRNA content was markedly decreased in HCC tissues compared with normal liver (Fig. 4B). The average mRNA abundance of \textit{BHMT}, \textit{CBS}, \textit{GNMT} and \textit{MS} in HCC tissues was 48%, 25%, 34% and 35%, respectively, of that determined in normal liver.

\textit{Hypermethylation of hepatic MAT1A promoter in human cirrhosis}

We have recently reported evidence showing that \textit{MAT1A} silencing during liver transformation is mediated by methylation of the gene promoter and histone deacetylation (26). Additionally, we have observed that \textit{MAT1A} promoter is hypermethylated in livers from \textit{Ccl}_{4}-induced cirrhotic rats (26). \textit{MAT1A} promoter methylation was assessed in ten cirrhotics (five with HCV cirrhosis and five with alcoholic cirrhosis) and five normal livers by methylation-sensitive restriction enzyme analysis as described in Materials and Methods. Fig. 5 shows a representative experiment with the results of \textit{MAT1A} promoter methylation obtained in two normal livers, two alcoholic and two HCV cirrhotic livers. The probe used in this study corresponds to a 0.89 kb \textit{DraI}-\textit{DraI} fragment (nucleotides −589 to −1479) of the human \textit{MAT1A} promoter (27), which contains a single \textit{MspI}/\textit{HpaII} restriction site (located at position −737). As can be observed in Fig. 5, digestion of control liver samples with \textit{DraI} and either \textit{MspI} or \textit{HpaII} yields one fragment of 0.74 kb which is recognized by this probe. In cirrhotic liver samples, after \textit{DraI} treatment, \textit{MspI} digestion generated the same 0.74 kb band present in control samples. However, \textit{HpaII} treatment yielded a 0.89 kb band, indicating that this enzyme did not cut and thus that \textit{MAT1A} promoter is hypermethylated at this site. \textit{MAT1A} promoter methylation was increased in the liver from all cirrhotic patients assessed independently of the etiology of the disease.

\textbf{Fig. 4.} A. Expression of \textit{MAT2A} in human hepatocarcinoma tissues and normal liver tissues as analyzed by Northern blotting. Hybridization with a 18S rRNA probe was carried out as loading control. B. Expression of \textit{BHMT}, \textit{CBS}, \textit{GNMT} and \textit{MS} in human hepatocarcinoma tissues and normal liver tissues as analyzed by quantitative RT-PCR. 18S ribosomal RNA was used as internal control. Samples and controls are as described in Materials and Methods.

\textbf{Fig. 5.} Methylation status of \textit{MAT1A} 5' region in normal liver and cirrhotic liver tissue. Restriction map of \textit{MAT1A} promoter indicating the location of the \textit{MspI}/\textit{HpaII} restriction site and the 0.88 kb \textit{DraI}-\textit{DraI} probe used in this analysis. Lower panel shows a representative Southern blot analysis of genomic DNA from normal, HCV and alcoholic cirrhotic liver after digestion with \textit{DraI} and \textit{MspI} (M) or \textit{HpaII} (H) performed with the probe described above. The molecular size of the bands detected with this probe is indicated.
Discussion

Our results show that the alterations of methionine metabolism in human liver cirrhosis can be ascribed to a marked reduction in the abundance of the mRNA of the main enzymes involved in the metabolism of this amino acid. Although not measured in the present work, the corresponding enzyme protein levels are likely to be reduced in a chronic situation such as liver cirrhosis. The reduction in MATIA mRNA content can explain the previously described increase in serum methionine (6,7) and abnormal clearance of methionine after an oral load of this amino acid (7) observed in patients with liver cirrhosis of different origins. In agreement with previous results (9), we observed an increase in tHcy in cirrhosis, which could be explained by the deficiencies in both cystathionine synthesis and homocysteine remethylation in the liver of these patients caused by the reduced abundance of CBS, MS and BHMT mRNA. In the liver, homocysteine may potentiate the fibrogenic effect of other agents such as ethanol and cytokines. Thus, we have recently shown that homocysteine is able to induce the expression of tissue inhibitor metalloproteinase-1 (TIMP-1) and α1(I) procollagen in rat hepatic stellate cells (31). The reduced content of CBS mRNA and the consequent deficiency of cystathionine synthesis could also explain the reduced content of hepatic GSH (10), plasma taurine (8) and urinary sulfate (7) in human liver cirrhosis. It has been previously demonstrated that in cirrhotic patients methionine clearance (8) and tHcy levels in plasma (9) correlate with the degree of liver dysfunction as determined by the Child-Pugh score. Accordingly, this work shows that in those patients with more severe disease, expressed as the Child-Pugh score, the expression of the main genes involved in methionine metabolism was more compromised.

Impairment of the metabolism of methionine in rats by feeding a diet deficient in choline, B12, folate and methionine leads to an enhancement of chemically-induced hepatocarcinogenesis (32) and to the spontaneous appearance of these cancers (33,34). These facts support the existence of a strong link between a defective one-carbon metabolism in liver and the development of neoplasia. A significant number of cirrhotic patients, especially those with HCV infection, develop HCC. In this regard the cirrhotic liver can be considered as a precancerous condition (35,36). The present observation showing that the mRNA content of MS and BHMT is reduced or non-detectable in a large majority of cirrhotic patients (only three cirrhotics had normal levels of BHMT mRNA and none of them had normal levels of MS mRNA), suggests that this defect in the remethylation of homocysteine may contribute to the development of HCC in cirrhosis.

In HCC tissues the mRNA content of GNM1, BHMT, MS and CBS was markedly diminished with respect to normal liver and, and as previously described (25), a switch in gene expression from MATIA to MAT2A was observed. This indicates that the methionine cycle and the transsulfuration pathway are both operating in HCC tissues; however, the capacity of these two pathways is markedly diminished as compared to that of a normal liver. First, while the products of MATIA are two MAT isoenzymes with high capacity to remove methionine from serum, the product of MAT2A is an enzyme with high affinity but low capacity to metabolize this amino acid (1,4). Second, the reduced abundance of the mRNA of CBS, BHMT and MS (25%, 48% and 35%, respectively, of that in normal liver) indicate a reduced capacity of the HCC tissue to catabolize homocysteine coming to the liver from other tissues and an impaired transsulfuration pathway as compared to that of normal liver. This reduced capacity to remethylate homocysteine, due to impaired expression of MS and BHMT, may explain the relative methionine dependence reported for transformed hepatic cells (37). In addition, the concomitant reduction in CBS expression, leading to elevated homocysteine levels, contributes to explain the increased production of homocysteine thiolactone, a highly reactive form of homocysteine (38), by transformed cells (39). Despite these deficiencies, the activity of the methionine cycle in HCC is probably sufficient to sustain the tumor necessities of AdoMet, methionine (through remethylation of homocysteine), folate cycling, choline metabolism and GSH content. Additionally, these changes in the pattern of expression of methionine metabolizing enzymes reflect the dedifferentiation of the hepatocarcinoma cell, and thus may be of diagnostic or prognostic value.

The finding that MAT1A promoter is hypermethylated in human liver cirrhosis, in an environment of global DNA hypomethylation (37), and our previous observations (26,40) showing that silencing of MAT1A is mediated by methylation of the gene and histone deacetylation, suggest that the reduced abundance of the mRNA of the enzymes involved in methionine metabolism in cirrhosis is the result of an active process and not only the consequence of an overall reduction of hepatic gene transcription. MAT1A promoter was hypermethylated in the cirrhotic patients independently of the etiology of the disease, and as we reported previously in a rat model of CCl4-induced cirrhosis (26), these observations indicate that this process can
be triggered under liver-damaging conditions, independently of the noxious agent.

Acknowledgements
This work was supported by grants from the Plan Nacional de I+D (SAF 96/0108, SAF 98/0132), Europharma and Knoll to J.M.M. NIH grant DK-51719 to S.C.L. FIS grant 98/1082 to JC. Gobierno de Navarra grant 923/98 to M.A. Avila. We thank Dr. Javier Diez for his help with homocysteine determinations. Technical support from E. Fernandez is acknowledged.

References


